𝗗𝗮𝗿 𝗔𝗹𝗱𝗮𝘄𝗮 𝗮𝗻𝗱 𝗢𝗡𝗖𝗼𝗻𝗰𝗲𝗽𝘁® 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝗘𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗟𝗶𝗰𝗲𝗻𝘀𝗶𝗻𝗴 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝘁𝗼 𝗘𝘅𝗽𝗮𝗻𝗱 𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗶𝗻 𝗠𝗘𝗡𝗔
Amman, Jordan / Coimbra, Portugal – 23 June 2025 – Dar Aldawa, a leading pharmaceutical company in the Middle East and North Africa (MENA) region, and ONConcept®, a strategic consortium in the field of oncology, have entered into an exclusive licensing and supply agreement for a key oncology product. The agreement was officially signed at Dar Aldawa’s headquarters in Amman, Jordan, on 11 May 2025 by Dr. Khaled Harb, CEO of Dar Aldawa, Dr. Sérgio Simões of Bluepharma and Dr. Lars Hallmayer of Welding.
Under the terms of the agreement, Dar Aldawa will oversee the product’s registration, commercialization, and distribution throughout the MENA region, while ONConcept® Consortium will be the exclusive supplier, with production at Bluepharma’s facilities in Portugal. This strategic partnership is aimed at increasing access to high-quality oncology treatments across the region, responding to a rising demand for effective and affordable cancer therapies.
𝗗𝗿. 𝗞𝗵𝗮𝗹𝗲𝗱 𝗛𝗮𝗿𝗯, 𝗖𝗘𝗢 𝗼𝗳 𝗗𝗮𝗿 𝗔𝗹𝗱𝗮𝘄𝗮 𝗚𝗿𝗼𝘂𝗽, 𝘀𝘁𝗮𝘁𝗲𝗱:
“We are pleased to partner with ONConcept® to reinforce our oncology portfolio and reinforce our presence in a critical therapeutic area. This collaboration reflects our commitment to providing reliable, high-quality treatment options that meet the evolving needs of healthcare systems and patients in the region.”
𝗢𝗻 𝗵𝗶𝘀 𝗯𝗲𝗵𝗮𝗹𝗳, 𝗦𝗲́𝗿𝗴𝗶𝗼 𝗦𝗶𝗺𝗼̃𝗲𝘀, 𝗩𝗶𝗰𝗲-𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁 𝗼𝗳 𝗕𝗹𝘂𝗲𝗽𝗵𝗮𝗿𝗺𝗮, 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝗲𝗱:
“This collaboration represents a strategic partnership that extends beyond product distribution — it aligns two organizations with a shared vision for improving healthcare in the region. By combining ONConcept®’s expertise in high-quality pharmaceutical development with Dar Aldawa’s deep understanding of the local healthcare landscape, we are creating a foundation for long-term impact in a critical therapeutic area. This agreement reinforces our commitment to expanding access to effective oncology treatments and building sustainable value for patients, providers, and health systems.”
This agreement underscores the companies’ shared dedication to quality, access, and long-term value for healthcare stakeholders across the MENA region.
